CancerProbe closes RMB100m Series B round

CancerProbe announced the completion of 100 million yuan in its Series B financing round. The proceeds will be used to accelerate the R&D pipeline, and advance the registration for listing on the STAR Market.

On July 7, CancerProbe announced the completion of 100 million yuan in its Series B financing round. The proceeds will be used to accelerate the R&D pipeline, and advance the registration for listing on the STAR Market.

CancerProbe is a developer of targeted cancer therapies intended to diagnose early cancer. The company develops new drugs that are used to screen for cancers, enabling users to screen for cancers via liquid biopsy and blood testing.

Sun Subeng, Founder and CEO of CancerProbe, said, “After completing this financing round, the company will further increase its investment in research and development and accelerate the registration process for a dozen solid tumor products, such as breast cancer blood screening and esophageal cancer blood screening.”

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/07/14/cancerprobe-closes-rmb100m-series-b-round/.

Leave a Reply

Please Login to Comment